Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | TOP2A | P11388 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6675831 | 0.89 | GRK6 (0.43) | SIGMAR1KDM4EACHEMEN1KMT2A | |
| SCHEMBL6678907 | 0.85 | ACHE (0.47) | KDM4EACHEALDH1A1MEN1KMT2A | |
| SCHEMBL6675351 | 0.83 | HRH3 (0.44) | SIGMAR1ACHEMEN1KMT2AHRH3 | |
| SCHEMBL6674354 | 0.83 | ACP1 (0.43) | KDM4EALDH1A1MEN1KMT2AHRH3 | |
| SCHEMBL6676198 | 0.83 | ACHE (0.38) | SIGMAR1ACHEALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL6679541 | 0.80 | TOP2A (0.48) | ACHEHRH3ACP1SMARCA2TOP2A | |
| SCHEMBL6677139 | 0.80 | ACHE (0.48) | KDM4EACHEALDH1A1MEN1KMT2A | |
| SCHEMBL6679085 | 0.79 | TOP2A (0.46) | ACHEMEN1KMT2AHRH3ACP1 | |
| SCHEMBL2246141 | 0.79 | ACP1 (0.36) | SIGMAR1ACHEHRH3ACP1SMARCA2 | |
| SCHEMBL2246009 | 0.79 | ACP1 (0.36) | SIGMAR1ACHEHRH3ACP1SMARCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1468688-A2 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | Auckland Uniservices Limited (NZ) | 2004-10-20 | — | — | EP | disclosed |
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | NPM1, DUOX1, NOX5 | SIGMAR1 380/4885KDM4E 1298/4885ACHE 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.